{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T02:43:32Z","timestamp":1792205012374,"version":"4.4.0"},"publisher-location":"Cham","reference-count":77,"publisher":"Springer Nature Switzerland","isbn-type":[{"value":"9783032231710","type":"print"},{"value":"9783032231727","type":"electronic"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1007\/978-3-032-23172-7_10","type":"book-chapter","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:42:36Z","timestamp":1777596156000},"page":"195-206","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Future Directions in Biotechnological and Pharmacological Applications of CAIs"],"prefix":"10.1007","author":[{"given":"Claudiu T.","family":"Supuran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neera","family":"Raghav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,1]]},"reference":[{"issue":"1","key":"10_CR1","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1080\/14756366.2021.1991336","volume":"37","author":"NS Abutaleb","year":"2022","unstructured":"Abutaleb NS, Elhassanny AEM, Nocentini A, Hewitt CS, Elkashif A, Cooper BR, Supuran CT, Seleem MN, Flaherty DP (2022) Repurposing FDA-approved sulphonamide carbonic anhydrase inhibitors for treatment of Neisseria gonorrhoeae. J Enzyme Inhib Med Chem 37(1):51\u201361","journal-title":"J Enzyme Inhib Med Chem"},{"key":"10_CR2","doi-asserted-by":"publisher","first-page":"4961","DOI":"10.1021\/acs.jmedchem.8b00420","volume":"61","author":"O Akgul","year":"2018","unstructured":"Akgul O, Di Cesare Mannelli L, Vullo D, Angeli A, Ghelardini C, Bartolucci G, Alfawaz Altamimi AS, Scozzafava A, Supuran CT, Carta F (2018) Discovery of novel nonsteroidal anti-inflammatory drugs and carbonic anhydrase inhibitors hybrids (NSAIDs-CAIs) for the management of rheumatoid arthritis. J Med Chem 61:4961\u20134977","journal-title":"J Med Chem"},{"key":"10_CR3","doi-asserted-by":"publisher","first-page":"4421","DOI":"10.1021\/cr200176r","volume":"112","author":"V Alterio","year":"2012","unstructured":"Alterio V, Di Fiore A, D\u2019Ambrosio K, Supuran CT, De Simone G (2012) Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms? Chem Rev 112:4421\u20134468","journal-title":"Chem Rev"},{"key":"10_CR4","doi-asserted-by":"publisher","first-page":"18579","DOI":"10.1021\/acs.jmedchem.5c01459","volume":"68","author":"A Ammara","year":"2025","unstructured":"Ammara A, Carone A, Lucarini L, Sgambellone S, Marri S, Villano S, Matucci R, Luga G, Fittipaldi C, Pecori R, Pieraccini G, Di Serio C, Garc\u00eda-Llorca A, Eysteinsson T, Kalinin S, Viita JAO, Urtti A, Carta F, Selleri S, Supuran CT (2025) Repurposing drug metabolites into dual \u03b2-adrenergic receptor-carbonic anhydrase modulators as potential tools for ocular disorders. J Med Chem 68:18579\u201318596","journal-title":"J Med Chem"},{"key":"10_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.117620","volume":"291","author":"A Ammara","year":"2025","unstructured":"Ammara A, Giovannuzzi S, Bonardi A, Abutaleb NS, Abouelkhair AA, Flaherty DP, Seleem MN, Capasso C, Gratteri P, Nocentini A, Supuran CT (2025) Redesigning oxazolidinones as carbonic anhydrase inhibitors against vancomycin-resistant enterococci. Eur J Med Chem 291:117620","journal-title":"Eur J Med Chem"},{"key":"10_CR6","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1080\/14756366.2022.2092729","volume":"37","author":"W An","year":"2022","unstructured":"An W, Holly KJ, Nocentini A, Imhoff RD, Hewitt CS, Abutaleb NS, Cao X, Seleem MN, Supuran CT, Flaherty DP (2022) Structure-activity relationship studies for inhibitors for vancomycin-resistant Enterococcus and human carbonic anhydrases. J Enzyme Inhib Med Chem 37:1838\u20131844","journal-title":"J Enzyme Inhib Med Chem"},{"key":"10_CR7","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1080\/13543776.2019.1661992","volume":"29","author":"A Angeli","year":"2019","unstructured":"Angeli A, Supuran CT (2019) Prostaglandin receptor agonists as antiglaucoma agents (a patent review 2013-2018). Expert Opin Ther Pat 29:793\u2013803","journal-title":"Expert Opin Ther Pat"},{"key":"10_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115783","volume":"260","author":"A Angeli","year":"2023","unstructured":"Angeli A, Micheli L, Turnaturi R, Pasquinucci L, Parenti C, Alterio V, Di Fiore A, De Simone G, Monti SM, Carta F, Di Cesare Mannelli L, Ghelardini C, Supuran CT (2023) Discovery of a novel series of potent carbonic anhydrase inhibitors with selective affinity for \u03bc opioid receptor for safer and long-lasting analgesia. Eur J Med Chem 260:115783","journal-title":"Eur J Med Chem"},{"issue":"3","key":"10_CR9","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","volume":"21","author":"M B\u00e9k\u00e9s","year":"2022","unstructured":"B\u00e9k\u00e9s M, Langley DR, Crews CM (2022) PROTAC targeted protein degraders: the past is prologue. Nat Rev Drug Discov 21(3):181\u2013200","journal-title":"Nat Rev Drug Discov"},{"key":"10_CR10","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.4155\/fmc-2023-0208","volume":"15","author":"G Benito","year":"2023","unstructured":"Benito G, D\u2019Agostino I, Carradori S, Fantacuzzi M, Agamennone M, Puca V, Grande R, Capasso C, Carta F, Supuran CT (2023) Erlotinib-containing benzenesulfonamides as anti-Helicobacter pylori agents through carbonic anhydrase inhibition. Future Med Chem 15:1865\u20131883","journal-title":"Future Med Chem"},{"key":"10_CR11","doi-asserted-by":"publisher","first-page":"7233","DOI":"10.1021\/acs.jmedchem.9b00845","volume":"62","author":"E Berrino","year":"2019","unstructured":"Berrino E, Milazzo L, Micheli L, Vullo D, Angeli A, Bozdag M, Nocentini A, Menicatti M, Bartolucci G, di Cesare Mannelli L, Ghelardini C, Supuran CT, Carta F (2019) Synthesis and evaluation of carbonic anhydrase inhibitors with carbon monoxide releasing properties for the management of rheumatoid arthritis. J Med Chem 62:7233\u20137249","journal-title":"J Med Chem"},{"key":"10_CR12","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.3390\/antiox12122044","volume":"12","author":"E Berrino","year":"2023","unstructured":"Berrino E, Carradori S, Carta F, Melfi F, Gallorini M, Poli G, Tuccinardi T, Fern\u00e1ndez-Bola\u00f1os JG, L\u00f3pez \u00d3, Petzer JP, Petzer A, Guglielmi P, Secci D, Supuran CT (2023) A multitarget approach against neuroinflammation: alkyl substituted coumarins as inhibitors of enzymes involved in neurodegeneration. Antioxidants (Basel) 12:2044","journal-title":"Antioxidants (Basel)"},{"key":"10_CR13","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1021\/acs.jmedchem.2c01706","volume":"66","author":"E Berrino","year":"2023","unstructured":"Berrino E, Micheli L, Carradori S, di Cesare Mannelli L, Guglielmi P, De Luca A, Carta F, Ghelardini C, Secci D, Supuran CT (2023) Novel insights on CAI-CORM hybrids: evaluation of the CO releasing properties and pain-relieving activity of differently substituted coumarins for the treatment of rheumatoid arthritis. J Med Chem 66:1892\u20131908","journal-title":"J Med Chem"},{"key":"10_CR14","doi-asserted-by":"publisher","first-page":"13143","DOI":"10.1021\/acs.jmedchem.2c00982","volume":"65","author":"A Bonardi","year":"2022","unstructured":"Bonardi A, Micheli L, Di Cesare Mannelli L, Ghelardini C, Gratteri P, Nocentini A, Supuran CT (2022) Development of hydrogen sulfide-releasing carbonic anhydrases IX- and XII-selective inhibitors with enhanced antihyperalgesic action in a rat model of arthritis. J Med Chem 65:13143\u201313157","journal-title":"J Med Chem"},{"key":"10_CR15","doi-asserted-by":"publisher","first-page":"10006","DOI":"10.3390\/ijms251810006","volume":"25","author":"A Bonardi","year":"2024","unstructured":"Bonardi A, Nocentini A, de Luca V, Capasso C, Elkaeed EB, Eldehna WM, Supuran CT (2024) Hydrogen sulfide-releasing carbonic anhydrase inhibitors effectively suppress cancer cell growth. Int J Mol Sci 25:10006","journal-title":"Int J Mol Sci"},{"key":"10_CR16","doi-asserted-by":"publisher","first-page":"9613","DOI":"10.1021\/acs.jmedchem.4c00740","volume":"67","author":"A Bonardi","year":"2024","unstructured":"Bonardi A, Nocentini A, Giovannuzzi S, Paoletti N, Ammara A, Bua S, Abutaleb NS, Abdelsattar AS, Capasso C, Gratteri P, Flaherty DP, Seleem MN, Supuran CT (2024) Development of penicillin-based carbonic anhydrase inhibitors targeting multidrug-resistant Neisseria gonorrhoeae. J Med Chem 67:9613\u20139627","journal-title":"J Med Chem"},{"key":"10_CR17","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1021\/acs.jmedchem.6b01607","volume":"60","author":"S Bua","year":"2017","unstructured":"Bua S, Di Cesare Mannelli L, Vullo D, Ghelardini C, Bartolucci G, Scozzafava A, Supuran CT, Carta F (2017) Design and synthesis of novel nonsteroidal anti-inflammatory drugs and carbonic anhydrase inhibitors hybrids (NSAIDs-CAIs) for the treatment of rheumatoid arthritis. J Med Chem 60:1159\u20131170","journal-title":"J Med Chem"},{"key":"10_CR18","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1021\/acs.jmedchem.9b01130","volume":"63","author":"S Bua","year":"2020","unstructured":"Bua S, Lucarini L, Micheli L, Menicatti M, Bartolucci G, Selleri S, Di Cesare Mannelli L, Ghelardini C, Masini E, Carta F, Gratteri P, Nocentini A, Supuran CT (2020) Bioisosteric development of multitarget nonsteroidal anti-inflammatory drug-carbonic anhydrases inhibitor hybrids for the management of rheumatoid arthritis. J Med Chem 63:2325\u20132342","journal-title":"J Med Chem"},{"key":"10_CR19","doi-asserted-by":"publisher","first-page":"5029","DOI":"10.3390\/ijms22095029","volume":"22","author":"I Bulli","year":"2021","unstructured":"Bulli I, Dettori I, Coppi E, Cherchi F, Venturini M, Di Cesare Mannelli L, Ghelardini C, Nocentini A, Supuran CT, Pugliese AM, Pedata F (2021) Role of carbonic anhydrase in cerebral ischemia and carbonic anhydrase inhibitors as putative protective agents. Int J Mol Sci 22:5029","journal-title":"Int J Mol Sci"},{"key":"10_CR20","doi-asserted-by":"publisher","first-page":"5667","DOI":"10.3390\/molecules20045667","volume":"20","author":"S Carradori","year":"2015","unstructured":"Carradori S, Mollica A, De Monte C, Ganese A, Supuran CT (2015) Nitric oxide donors and selective carbonic anhydrase inhibitors: a dual pharmacological approach for the treatment of glaucoma, cancer and osteoporosis. Molecules 20:5667\u20135679","journal-title":"Molecules"},{"key":"10_CR21","doi-asserted-by":"publisher","first-page":"5511","DOI":"10.1021\/jm1003667","volume":"53","author":"F Carta","year":"2010","unstructured":"Carta F, Temperini C, Innocenti A, Scozzafava A, Kaila K, Supuran CT (2010) Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem 53:5511\u20135522","journal-title":"J Med Chem"},{"key":"10_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/ardp.70020","volume":"358","author":"A Costa","year":"2025","unstructured":"Costa A, Bozdag M, Renzi G, Rani B, Passani MB, Angeli A, Provensi G, Carta F, Supuran CT (2025) Hitting two birds with one stone: dual modulation of brain carbonic anhydrases and histone deacetylases boosts memory consolidation. Arch Pharm (Weinheim) 358:e70020","journal-title":"Arch Pharm (Weinheim)"},{"key":"10_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.118404","volume":"303","author":"A Costa","year":"2025","unstructured":"Costa A, Provensi G, Titi C, Leri M, Bucciantini M, Ferraroni M, Keeton AB, Moore AM, Piazza GA, Abadi AH, Angeli A, Supuran CT (2025) Exploring dual inhibitors carbonic anhydrases and phosphodiesterase 5 as potential agents for treatment Alzheimer\u2019s disease. Eur J Med Chem 303:118404","journal-title":"Eur J Med Chem"},{"key":"10_CR24","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1039\/C4CC07320G","volume":"51","author":"K D\u2019Ambrosio","year":"2015","unstructured":"D\u2019Ambrosio K, Carradori S, Monti SM, Buonanno M, Secci D, Vullo D, Supuran CT, De Simone G (2015) Out of the active site binding pocket for carbonic anhydrase inhibitors. Chem Commun (Camb) 51:302\u2013305","journal-title":"Chem Commun (Camb)"},{"key":"10_CR25","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1021\/acs.chemrev.4c00278","volume":"125","author":"K D\u2019Ambrosio","year":"2025","unstructured":"D\u2019Ambrosio K, Di Fiore A, Alterio V, Langella E, Monti SM, Supuran CT, De Simone G (2025) Multiple binding modes of inhibitors to human carbonic anhydrases: an update on the design of isoform-specific modulators of activity. Chem Rev 125:150\u2013222","journal-title":"Chem Rev"},{"key":"10_CR26","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jinorgbio.2011.11.017","volume":"111","author":"G De Simone","year":"2012","unstructured":"De Simone G, Supuran CT (2012) (In)organic anions as carbonic anhydrase inhibitors. J Inorg Biochem 111:117\u2013129","journal-title":"J Inorg Biochem"},{"key":"10_CR27","doi-asserted-by":"publisher","first-page":"894","DOI":"10.3109\/14756366.2015.1113407","volume":"31","author":"L Di Cesare Mannelli","year":"2016","unstructured":"Di Cesare Mannelli L, Micheli L, Carta F, Cozzi A, Ghelardini C, Supuran CT (2016) Carbonic anhydrase inhibition for the management of cerebral ischemia: in vivo evaluation of sulfonamide and coumarin inhibitors. J Enzyme Inhib Med Chem 31:894\u2013899","journal-title":"J Enzyme Inhib Med Chem"},{"key":"10_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.118304","volume":"302","author":"MAZ El-Attar","year":"2026","unstructured":"El-Attar MAZ, Afifi OS, Ismail A, Kamel YN, Yassin HA, Nomeir HM, Nematalla HA, Angeli A, Labib HF, Eldehna WM, Supuran CT, Belal ASF, Elzahhar PA, Hassan NW (2026) Click-modifiable isatin hydrazones as COX-2, VEGFR-2, and carbonic anhydrase inhibitors: a multi-target approach to cancer therapy. Eur J Med Chem 302:118304","journal-title":"Eur J Med Chem"},{"key":"10_CR29","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1021\/acsptsci.5c00011","volume":"8","author":"PA Elzahhar","year":"2025","unstructured":"Elzahhar PA, Nematalla HA, Abouayana MA, El Ashry ESH, Balbaa M, Petreni A, Nassra R, Yassin HA, Kamel YN, Elrewiny MA, Agami MA, Makkar M, Sai M, Merk D, Labib HF, Spagnuolo R, Naldi M, Bartolini M, El-Hawash SA, Supuran CT, Belal ASF, El-Yazbi AF (2025) Multi-target glitazones for modulating peroxisome proliferator-activated receptor-\u03b3, cyclooxygenase-2, and carbonic anhydrases for the management of metabolic dysfunction. ACS Pharmacol Transl Sci 8:1627\u20131658","journal-title":"ACS Pharmacol Transl Sci"},{"key":"10_CR30","doi-asserted-by":"publisher","first-page":"4316","DOI":"10.1039\/D5MD00109A","volume":"16","author":"S Filiberti","year":"2025","unstructured":"Filiberti S, Renzi G, Carta F, Fantacuzzi M, D\u2019Agostino I, Benito G, Angeli A, Massardi ML, Simsek R, Capasso C, Carradori S, Ronca R, Supuran CT (2025) Pegylation approach applied to erlotinib-carbonic anhydrase inhibitors hybrids towards anticancer agents. RSC Med Chem 16:4316\u20134339","journal-title":"RSC Med Chem"},{"key":"10_CR31","doi-asserted-by":"publisher","first-page":"23676","DOI":"10.1021\/acs.jmedchem.5c01911","volume":"68","author":"L Gioiello","year":"2025","unstructured":"Gioiello L, Di Martino RMC, Pirali T (2025) Expanding the scope of PROTACs: opportunities and challenges in topical delivery. J Med Chem 68:23676\u201323689","journal-title":"J Med Chem"},{"key":"10_CR32","doi-asserted-by":"publisher","first-page":"4170","DOI":"10.1021\/acs.jmedchem.4c00045","volume":"67","author":"S Giovannuzzi","year":"2024","unstructured":"Giovannuzzi S, Chavarria D, Provensi G, Leri M, Bucciantini M, Carradori S, Bonardi A, Gratteri P, Borges F, Nocentini A, Supuran CT (2024) Dual inhibitors of brain carbonic anhydrases and monoamine oxidase-B efficiently protect against amyloid-\u03b2-induced neuronal toxicity, oxidative stress, and mitochondrial dysfunction. J Med Chem 67:4170\u20134193","journal-title":"J Med Chem"},{"key":"10_CR33","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41568-025-00817-8","volume":"25","author":"M Hinterndorfer","year":"2025","unstructured":"Hinterndorfer M, Spiteri VA, Ciulli A, Winter GE (2025) Targeted protein degradation for cancer therapy. Nat Rev Cancer 25:493\u2013516","journal-title":"Nat Rev Cancer"},{"key":"10_CR34","doi-asserted-by":"publisher","first-page":"689","DOI":"10.4155\/fmc-2023-0321","volume":"16","author":"A Kumar","year":"2024","unstructured":"Kumar A, Arya P, Giovannuzzi S, Mohan B, Raghav N, Supuran CT, Sharma PK (2024) Novel 1,2,4-triazoles as selective carbonic anhydrase inhibitors showing ancillary anticathepsin B activity. Future Med Chem 16:689\u2013706","journal-title":"Future Med Chem"},{"key":"10_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0163-7258(96)00198-2","volume":"74","author":"S Lindskog","year":"1997","unstructured":"Lindskog S (1997) Structure and mechanism of carbonic anhydrase. Pharmacol Ther 74:1\u201320","journal-title":"Pharmacol Ther"},{"key":"10_CR36","doi-asserted-by":"publisher","first-page":"3364","DOI":"10.1158\/0008-5472.CAN-10-4261","volume":"71","author":"Y Lou","year":"2011","unstructured":"Lou Y, McDonald PC, Oloumi A, Chia S, Ostlund C, Ahmadi A, Kyle A, Auf dem Keller U, Leung S, Huntsman D, Clarke B, Sutherland BW, Waterhouse D, Bally M, Roskelley C, Overall CM, Minchinton A, Pacchiano F, Carta F, Scozzafava A, Touisni N, Winum JY, Supuran CT, Dedhar S (2011) Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res 71:3364\u20133376","journal-title":"Cancer Res"},{"key":"10_CR37","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.canlet.2013.01.020","volume":"333","author":"N Lounnas","year":"2013","unstructured":"Lounnas N, Rosilio C, Nebout M, Mary D, Griessinger E, Neffati Z, Chiche J, Spits H, Hagenbeek TJ, Asnafi V, Poulsen SA, Supuran CT, Peyron JF, Imbert V (2013) Pharmacological inhibition of carbonic anhydrase XII interferes with cell proliferation and induces cell apoptosis in T-cell lymphomas. Cancer Lett 333:76\u201388","journal-title":"Cancer Lett"},{"key":"10_CR38","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1152\/physrev.1967.47.4.595","volume":"47","author":"TH Maren","year":"1967","unstructured":"Maren TH (1967) Carbonic anhydrase: chemistry, physiology, and inhibition. Physiol Rev 47:595\u2013781","journal-title":"Physiol Rev"},{"key":"10_CR39","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1021\/ja809683v","volume":"131","author":"A Maresca","year":"2009","unstructured":"Maresca A, Temperini C, Vu H, Pham NB, Poulsen SA, Scozzafava A, Quinn RJ, Supuran CT (2009) Non-zinc mediated inhibition of carbonic anhydrases: coumarins are a new class of suicide inhibitors. J Am Chem Soc 131:3057\u20133062","journal-title":"J Am Chem Soc"},{"key":"10_CR40","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1097\/COC.0000000000000691","volume":"43","author":"PC McDonald","year":"2020","unstructured":"McDonald PC, Chia S, Bedard PL, Chu Q, Lyle M, Tang L, Singh M, Zhang Z, Supuran CT, Renouf DJ, Dedhar S (2020) A phase 1 study of SLC-0111, a novel inhibitor of carbonic anhydrase IX, in patients with advanced solid tumors. Am J Clin Oncol 43:484\u2013490","journal-title":"Am J Clin Oncol"},{"issue":"14","key":"10_CR41","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.3390\/cancers14143297","volume":"14","author":"PC McDonald","year":"2022","unstructured":"McDonald PC, Chafe SC, Supuran CT, Dedhar S (2022) Cancer therapeutic targeting of hypoxia induced carbonic anhydrase IX: from bench to bedside. Cancers (Basel) 14(14):3297","journal-title":"Cancers (Basel)"},{"key":"10_CR42","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1080\/17460441.2021.1922384","volume":"16","author":"F Mincione","year":"2021","unstructured":"Mincione F, Nocentini A, Supuran CT (2021) Advances in the discovery of novel agents for the treatment of glaucoma. Expert Opin Drug Discov 16:1209\u20131225","journal-title":"Expert Opin Drug Discov"},{"key":"10_CR43","doi-asserted-by":"publisher","first-page":"5380","DOI":"10.1021\/acs.jmedchem.8b00625","volume":"61","author":"A Nocentini","year":"2018","unstructured":"Nocentini A, Ceruso M, Bua S, Lomelino CL, Andring JT, McKenna R, Lanzi C, Sgambellone S, Pecori R, Matucci R, Filippi L, Gratteri P, Carta F, Masini E, Selleri S, Supuran CT (2018) Discovery of \u03b2-adrenergic receptors blocker-carbonic anhydrase inhibitor hybrids for multitargeted antiglaucoma therapy. J Med Chem 61:5380\u20135394","journal-title":"J Med Chem"},{"issue":"1","key":"10_CR44","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1080\/14756366.2021.1882453","volume":"36","author":"A Nocentini","year":"2021","unstructured":"Nocentini A, Angeli A, Carta F, Winum JY, Zalubovskis R, Carradori S, Capasso C, Donald WA, Supuran CT (2021) Reconsidering anion inhibitors in the general context of drug design studies of modulators of activity of the classical enzyme carbonic anhydrase. J Enzyme Inhib Med Chem 36(1):561\u2013580","journal-title":"J Enzyme Inhib Med Chem"},{"key":"10_CR45","doi-asserted-by":"publisher","first-page":"16873","DOI":"10.1021\/acs.jmedchem.4c01866","volume":"67","author":"A Nocentini","year":"2024","unstructured":"Nocentini A, Costa A, Bonardi A, Ammara A, Giovannuzzi S, Petreni A, Bartolucci G, Rani B, Leri M, Bucciantini M, Fern\u00e1ndez-Bola\u00f1os JG, L\u00f3pez \u00d3, Passani MB, Provensi G, Gratteri P, Supuran CT (2024) Enhanced recognition memory through dual modulation of brain carbonic anhydrases and cholinesterases. J Med Chem 67:16873\u201316898","journal-title":"J Med Chem"},{"issue":"1","key":"10_CR46","doi-asserted-by":"publisher","first-page":"2366236","DOI":"10.1080\/14756366.2024.2366236","volume":"39","author":"A Nocentini","year":"2024","unstructured":"Nocentini A, Di Porzio A, Bonardi A, Bazzicalupi C, Petreni A, Biver T, Bua S, Marzano S, Amato J, Pagano B, Iaccarino N, De Tito S, Amente S, Supuran CT, Randazzo A, Gratteri P (2024) Development of a multi-targeted chemotherapeutic approach based on G-quadruplex stabilisation and carbonic anhydrase inhibition. J Enzyme Inhib Med Chem 39(1):2366236","journal-title":"J Enzyme Inhib Med Chem"},{"key":"10_CR47","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1021\/acs.jmedchem.2c01843","volume":"66","author":"CB O\u2019Herin","year":"2023","unstructured":"O\u2019Herin CB, Moriuchi YW, Bemis TA, Kohlbrand AJ, Burkart MD, Cohen SM (2023) Development of human carbonic anhydrase II heterobifunctional degraders. J Med Chem 66:2789\u20132803","journal-title":"J Med Chem"},{"key":"10_CR48","doi-asserted-by":"publisher","DOI":"10.1002\/ardp.202400776","volume":"358","author":"R Paciotti","year":"2025","unstructured":"Paciotti R, Carradori S, Angeli A, D\u2019Agostino I, Ferraroni M, Coletti C, Supuran CT (2025) Unprecedented carbonic anhydrase inhibition mechanism: targeting histidine 64 side chain through a halogen bond. Arch Pharm (Weinheim) 358:e2400776","journal-title":"Arch Pharm (Weinheim)"},{"key":"10_CR49","doi-asserted-by":"publisher","first-page":"3289","DOI":"10.1021\/acs.jmedchem.5c03157","volume":"69","author":"N Paoletti","year":"2026","unstructured":"Paoletti N, Giovannuzzi S, Gasparrini M, Ammara A, Zaroon Z, Raffaelli N, De Nigris F, Gratteri P, Supuran CT, Nocentini A (2026) Targeting metabolic and pH regulatory pathways in cancer via dual inhibition of nicotinamide phosphoribosyltransferase and carbonic anhydrases IX and XII. J Med Chem 69:3289\u20133314. https:\/\/doi.org\/10.1021\/acs.jmedchem.5c03157","journal-title":"J Med Chem"},{"key":"10_CR50","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1080\/13543776.2024.2367005","volume":"34","author":"L Pisano","year":"2024","unstructured":"Pisano L, Giovannuzzi S, Supuran CT (2024) Management of Neisseria gonorrhoeae infection: from drug resistance to drug repurposing. Expert Opin Ther Pat 34:511\u2013524","journal-title":"Expert Opin Ther Pat"},{"key":"10_CR51","doi-asserted-by":"publisher","DOI":"10.1002\/ardp.70062","volume":"358","author":"G Renzi","year":"2025","unstructured":"Renzi G, Angeli A, Selleri S, Spadini C, Mezzasalma N, Hull MT, Kelly SL, Capasso C, Cabassi CS, Carta F, Supuran CT (2025) Design and synthesis of ketoconazole derivatives as innovative anti-infective agents. Arch Pharm (Weinheim) 358:e70062","journal-title":"Arch Pharm (Weinheim)"},{"key":"10_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.118107","volume":"300","author":"G Renzi","year":"2025","unstructured":"Renzi G, McDonald PC, Awrey S, Tavakoli H, Bokhari Z, Lyle M, Zhang Z, Ferraroni M, Dedhar S, Supuran CT, Angeli A (2025) Dual inhibition of carbonic anhydrase IX and glutathione peroxidase 4 as a novel strategy for ferroptosis-induced tumor cell death. Eur J Med Chem 300:118107","journal-title":"Eur J Med Chem"},{"key":"10_CR53","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/s41573-019-0047-y","volume":"18","author":"M Schapira","year":"2019","unstructured":"Schapira M, Calabrese MF, Bullock AN, Crews CM (2019) Targeted protein degradation: expanding the toolbox. Nat Rev Drug Discov 18:949\u2013963","journal-title":"Nat Rev Drug Discov"},{"key":"10_CR54","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/nrd2467","volume":"7","author":"CT Supuran","year":"2008","unstructured":"Supuran CT (2008) Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 7:168\u2013181","journal-title":"Nat Rev Drug Discov"},{"key":"10_CR55","doi-asserted-by":"publisher","first-page":"345","DOI":"10.3109\/14756366.2015.1122001","volume":"31","author":"CT Supuran","year":"2016","unstructured":"Supuran CT (2016) How many carbonic anhydrase inhibition mechanisms exist? J Enzyme Inhib Med Chem 31:345\u2013360","journal-title":"J Enzyme Inhib Med Chem"},{"key":"10_CR56","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1080\/14737175.2016.1193009","volume":"16","author":"CT Supuran","year":"2016","unstructured":"Supuran CT (2016) Carbonic anhydrase inhibition and the management of neuropathic pain. Expert Rev Neurother 16:961\u2013968","journal-title":"Expert Rev Neurother"},{"key":"10_CR57","first-page":"561","volume":"10","author":"CT Supuran","year":"2018","unstructured":"Supuran CT (2018) Carbonic anhydrase activators. Future. Med Chem 10:561\u2013573","journal-title":"Med Chem"},{"key":"10_CR58","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1080\/13543776.2018.1523897","volume":"28","author":"CT Supuran","year":"2018","unstructured":"Supuran CT (2018) Carbonic anhydrase inhibitors and their potential in a range of therapeutic areas. Expert Opin Ther Pat 28:709\u2013712","journal-title":"Expert Opin Ther Pat"},{"key":"10_CR59","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1080\/13543776.2018.1519023","volume":"28","author":"CT Supuran","year":"2018","unstructured":"Supuran CT (2018) Applications of carbonic anhydrases inhibitors in renal and central nervous system diseases. Expert Opin Ther Pat 28:713\u2013721","journal-title":"Expert Opin Ther Pat"},{"key":"10_CR60","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1080\/13543776.2019.1671353","volume":"29","author":"CT Supuran","year":"2019","unstructured":"Supuran CT (2019) Agents for the prevention and treatment of age-related macular degeneration and macular edema: a literature and patent review. Expert Opin Ther Pat 29:761\u2013767","journal-title":"Expert Opin Ther Pat"},{"key":"10_CR61","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1080\/17425255.2020.1743679","volume":"16","author":"CT Supuran","year":"2020","unstructured":"Supuran CT (2020) An update on drug interaction considerations in the therapeutic use of carbonic anhydrase inhibitors. Expert Opin Drug Metab Toxicol 16:297\u2013307","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10_CR62","doi-asserted-by":"publisher","first-page":"603","DOI":"10.2147\/JEP.S265620","volume":"12","author":"CT Supuran","year":"2020","unstructured":"Supuran CT (2020) Experimental carbonic anhydrase inhibitors for the treatment of hypoxic tumors. J Exp Pharmacol 12:603\u2013617","journal-title":"J Exp Pharmacol"},{"key":"10_CR63","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1080\/13543784.2021.2014813","volume":"30","author":"CT Supuran","year":"2021","unstructured":"Supuran CT (2021) Carbonic anhydrase inhibitors: an update on experimental agents for the treatment and imaging of hypoxic tumors. Expert Opin Investig Drugs 30:1197\u20131208","journal-title":"Expert Opin Investig Drugs"},{"key":"10_CR64","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1042\/CS20210040","volume":"135","author":"CT Supuran","year":"2021","unstructured":"Supuran CT (2021) Emerging role of carbonic anhydrase inhibitors. Clin Sci (Lond) 135:1233\u20131249","journal-title":"Clin Sci (Lond)"},{"key":"10_CR65","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1080\/14756366.2021.1945049","volume":"36","author":"CT Supuran","year":"2021","unstructured":"Supuran CT (2021) Multitargeting approaches involving carbonic anhydrase inhibitors: hybrid drugs against a variety of disorders. J Enzyme Inhib Med Chem 36:1702\u20131714","journal-title":"J Enzyme Inhib Med Chem"},{"key":"10_CR66","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1080\/14756366.2022.2121393","volume":"37","author":"CT Supuran","year":"2022","unstructured":"Supuran CT (2022) Anti-obesity carbonic anhydrase inhibitors: challenges and opportunities. J Enzyme Inhib Med Chem 37:2478\u20132488","journal-title":"J Enzyme Inhib Med Chem"},{"key":"10_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2023.129411","volume":"93","author":"CT Supuran","year":"2023","unstructured":"Supuran CT (2023) A simple yet multifaceted 90 years old, evergreen enzyme: carbonic anhydrase, its inhibition and activation. Bioorg Med Chem Lett 93:129411","journal-title":"Bioorg Med Chem Lett"},{"key":"10_CR68","doi-asserted-by":"publisher","first-page":"1326633","DOI":"10.3389\/fmolb.2023.1326633","volume":"10","author":"CT Supuran","year":"2023","unstructured":"Supuran CT (2023) Carbonic anhydrase versatility: from pH regulation to CO2 sensing and metabolism. Front Mol Biosci 10:1326633","journal-title":"Front Mol Biosci"},{"key":"10_CR69","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1080\/14728222.2023.2263914","volume":"27","author":"CT Supuran","year":"2023","unstructured":"Supuran CT (2023) An overview of novel antimicrobial carbonic anhydrase inhibitors. Expert Opin Ther Targets 27:897\u2013910","journal-title":"Expert Opin Ther Targets"},{"key":"10_CR70","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1080\/13543776.2023.2245971","volume":"33","author":"CT Supuran","year":"2023","unstructured":"Supuran CT (2023) Targeting carbonic anhydrases for the management of hypoxic metastatic tumors. Expert Opin Ther Pat 33:701\u2013720","journal-title":"Expert Opin Ther Pat"},{"key":"10_CR71","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1080\/13543776.2023.2201432","volume":"33","author":"CT Supuran","year":"2023","unstructured":"Supuran CT (2023) Antiprotozoal drugs: challenges and opportunities. Expert Opin Ther Pat 33:133\u2013136","journal-title":"Expert Opin Ther Pat"},{"key":"10_CR72","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1080\/17425255.2024.2328152","volume":"20","author":"CT Supuran","year":"2024","unstructured":"Supuran CT (2024) Drug interactions of carbonic anhydrase inhibitors and activators. Expert Opin Drug Metab Toxicol 20:143\u2013155","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10_CR73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13543784.2024.2334714","volume":"27","author":"CT Supuran","year":"2024","unstructured":"Supuran CT (2024) Novel carbonic anhydrase inhibitors for the treatment of Helicobacter pylori infection. Expert Opin Investig Drugs 27:1\u201310. https:\/\/doi.org\/10.1080\/13543784.2024.2334714","journal-title":"Expert Opin Investig Drugs"},{"key":"10_CR74","first-page":"383","volume":"55","author":"CT Supuran","year":"2024","unstructured":"Supuran CT (2024) Challenges for developing bacterial CA inhibitors as novel antibiotics. Enzyme 55:383\u2013411","journal-title":"Enzyme"},{"key":"10_CR75","doi-asserted-by":"publisher","DOI":"10.1124\/pharmrev.124.001125","volume":"77","author":"CT Supuran","year":"2025","unstructured":"Supuran CT (2025) Multi- and polypharmacology of carbonic anhydrase inhibitors. Pharmacol Rev 77:100004","journal-title":"Pharmacol Rev"},{"key":"10_CR76","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1021\/acsmedchemlett.5c00443","volume":"16","author":"CT Supuran","year":"2025","unstructured":"Supuran CT (2025) Human carbonic anhydrase inhibitors. ACS Med Chem Lett 16:1889\u20131895","journal-title":"ACS Med Chem Lett"},{"key":"10_CR77","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.febslet.2004.10.043","volume":"577","author":"E Svastov\u00e1","year":"2004","unstructured":"Svastov\u00e1 E, Hul\u00edkov\u00e1 A, Rafajov\u00e1 M, Zat\u2019ovicov\u00e1 M, Gibadulinov\u00e1 A, Casini A, Cecchi A, Scozzafava A, Supuran CT, Pastorek J, Pastorekov\u00e1 S (2004) Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett 577:439\u2013445","journal-title":"FEBS Lett"}],"container-title":["Subcellular Biochemistry","Carbonic Anhydrase Inhibitors"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-032-23172-7_10","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:42:37Z","timestamp":1777596157000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-032-23172-7_10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9783032231710","9783032231727"],"references-count":77,"URL":"https:\/\/doi.org\/10.1007\/978-3-032-23172-7_10","relation":{},"ISSN":["0306-0225","2542-8810"],"issn-type":[{"value":"0306-0225","type":"print"},{"value":"2542-8810","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"1 May 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}